Study to Compare the Bioavailability, Safety and Tolerability of XM17 in Healthy, Down Regulated Young Women

Inclusion Criteria: * Having signed written informed consent * Healthy female subjects of any racial origin * 18-39 years at the time of screening * Body mass index (BMI) between 18-29 kg/m2 and a body weight of ≥ 50 kg * Use of oral contraceptives for contraceptive purposes only and not for regularization of menstrual cycle, for at least 3 months * Normal uterus and two functioning ovaries * Agrees to use an adequate method of contraception during the study * Non-smoking or moderate smokers of \< 10 cigarettes a day Exclusion Criteria: * Pregnancy * Polycystic ovary syndrome, impaired ovarian function, severe endometriosis class III or IV, submucosal myoma uteri * History of endocrine abnormalities with treatment within the last six months. * Contraindications for the use of gonadotropins and goserelin * Breast-feeding or being within a period of 2 months after delivery or abortion. * Use of an injectable hormonal contraceptive within a period of 6 months prior to screening * Treatment in the previous three months with any drug known to have a well-defined potential for toxicity to a major organ